Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder

Abstract

The rates of opioid use and opioid related deaths are escalating in the United States. Despite this, evidence-based treatments for Opioid Use Disorder are underutilized. There are three medications FDA approved for treatment of Opioid Use Disorder: Methadone, Buprenorphine, and Naltrexone. This article reviews the history, criteria, and mechanisms associated with Opioid Use Disorder. Pertinent pharmacology considerations, treatment strategies, efficacy, safety, and challenges of Methadone, Buprenorphine, and Naltrexone are outlined. Lastly, a practical decision making algorithm is discussed to address pertinent psychiatric and medical comorbidities when prescribing pharmacology for Opioid Use Disorder.

Keywords

Opioid Crisis - Opioid Maintenance Therapy - Opioid Use Disorder - Methadone - Buprenorphine - Naltrexone

Publikationsverlauf

Artikel online veröffentlicht:
07. Juni 2024

• References

• 1 Oesterle TS, Kolla BP, Rummans TA, Gold MS. Medication-assisted therapies for opioid use disorders in patients with chronic pain. J Neurol Sci 2020; 411: 116728
• 2 Brook K, Bennett J, Desai SP. The chemical history of morphine: an 8000-year journey, from resin to de-novo synthesis. J Anesth Hist 2017; 3 (02) 50-55
• 3 Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci U S A 1993; 90 (12) 5391-5393
• 4 Sabatowski R, Schäfer D, Kasper SM, Brunsch H, Radbruch L. Pain treatment: a historical overview. Curr Pharm Des 2004; 10 (07) 701-716
• 5 Kolodny A, Courtwright DT, Hwang CS. et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health 2015; 36: 559-574
• 6 Puntillo K, Neighbor M, O'Neil N, Nixon R. Accuracy of emergency nurses in assessment of patients' pain. Pain Manag Nurs 2003; 4 (04) 171-175
• 7 Max MB. Improving outcomes of analgesic treatment: is education enough?. Ann Intern Med 1990; 113 (11) 885-889
• 8 Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep 2018; 67 (5152): 1419-1427
• 9 National Survey on Drug Use and Health. 2020 National Survey on Drug Use and Health Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2021. Accessed November 22, 2022 at: https://www.samhsa.gov/data/report/2020-nsduh-detailed-tables
• 10 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022
• 11 Jalabert M, Bourdy R, Courtin J. et al. Neuronal circuits underlying acute morphine action on dopamine neurons. Proc Natl Acad Sci U S A 2011; 108 (39) 16446-16450
• 12 Jones JD, Levin CJ, Mumtaz M, Comer SD. Neurobiology of opioids. In: Brady KT, Levin FR, Marc Galanter, Kleber HD. eds. The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment. 6th ed.. American Psychiatric Association Publishing; 2021
• 13 Bergeria CL, Strain EC. Opioid use disorder: pernicious and persistent. Am J Psychiatry 2022; 179 (10) 708-714
• 14 Burma NE, Kwok CH, Trang T. Therapies and mechanisms of opioid withdrawal. Pain Manag (Lond) 2017; 7 (06) 455-459
• 15 Feltenstein MW, See RE. The neurocircuitry of addiction: an overview. Br J Pharmacol 2008; 154 (02) 261-274
• 16 Baler RD, Volkow ND. Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med 2006; 12 (12) 559-566
• 17 Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162 (08) 1403-1413
• 18 Trang T, Al-Hasani R, Salvemini D, Salter MW, Gutstein H, Cahill CM. Pain and poppies: the good, the bad, and the ugly of opioid analgesics. J Neurosci 2015; 35 (41) 13879-13888
• 19 Corder G, Castro DC, Bruchas MR, Scherrer G. Endogenous and exogenous opioids in pain. Annu Rev Neurosci 2018; 41: 453-473
• 20 Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci 2012; 35 (01) 68-77
• 21 Le Merrer J, Plaza-Zabala A, Del Boca C, Matifas A, Maldonado R, Kieffer BL. Deletion of the δ opioid receptor gene impairs place conditioning but preserves morphine reinforcement. Biol Psychiatry 2011; 69 (07) 700-703
• 22 Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology 2018; 43 (13) 2514-2520
• 23 Badal S, Turfus S, Rajnarayanan R, Wilson-Clarke C, Sandiford SL. Analysis of natural product regulation of opioid receptors in the treatment of human disease. Pharmacol Ther 2018; 184: 51-80
• 24 Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 2011; 115 (06) 1363-1381
• 25 Williams J. Basic opioid pharmacology. Rev Pain 2008; 1 (02) 2-5
• 26 Schmid CL, Kennedy NM, Ross NC. et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell 2017; 171 (05) 1165-1175.e13
• 27 Raehal KM, Bohn LM. β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb Exp Pharmacol 2014; 219: 427-443
• 28 Kroenke K, Alford DP, Argoff C. et al. Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: a consensus panel report. Pain Med 2019; 20 (04) 724-735
• 29 Chang DC, Klimas J, Wood E, Fairbairn N. A case of opioid overdose and subsequent death after medically supervised withdrawal: the problematic role of rapid tapers for opioid use disorder. J Addict Med 2018; 12 (01) 80-83
• 30 Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies–tackling the opioid-overdose epidemic. N Engl J Med 2014; 370 (22) 2063-2066
• 31 Oesterle TS, Thusius NJ, Rummans TA, Gold MS. Medication-assisted treatment for opioid-use disorder. Mayo Clin Proc 2019; 94 (10) 2072-2086
• 32 Strain EC, Stoller KB. Methadone and buprenorphine maintenance treatment of opioid-related disorders. In: Brady KT, Levin FR, Galanter M, Kleber HD. eds. The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment. 6th ed.. American Psychiatric Association Publishing; 2021
• 33 Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41 (14) 1153-1193
• 34 Walsh SL, Strain ED. Pharmacology of Methadone in the Treatment of Opioid Dependence. Baltimore, MD: Hopkins Press; 2005
• 35 Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1995; 56 (02) PL45-PL50
• 36 Haroutiunian S, McNicol ED, Lipman AG. Methadone for chronic non-cancer pain in adults. Cochrane Database Syst Rev 2012; 11 (11) CD008025
• 37 Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med 1966; 118 (04) 304-309
• 38 Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med 2000; 67 (5-6): 347-364
• 39 Ball J, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer New York, NY; 2012
• 40 Chou R, Cruciani RA, Fiellin DA. et al; American Pain Society, Heart Rhythm Society. Methadone safety: a clinical practice guideline from the American Pain Society and College on problems of drug dependence, in collaboration with the Heart Rhythm Society. J Pain 2014; 15 (04) 321-337
• 41 Wakeman SE, Larochelle MR, Ameli O. et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open 2020; 3 (02) e1920622
• 42 Farrell M, Ward J, Mattick R. et al. Methadone maintenance treatment in opiate dependence: a review. BMJ 1994; 309 (6960): 997-1001
• 43 Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 2009 (03) CD002209
• 44 Larochelle MR, Bernson D, Land T. et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med 2018; 169 (03) 137-145
• 45 Molero Y, Zetterqvist J, Binswanger IA, Hellner C, Larsson H, Fazel S. Medications for alcohol and opioid use disorders and risk of suicidal behavior, accidental overdoses, and crime. Am J Psychiatry 2018; 175 (10) 970-978
• 46 Carley JA, Oesterle T. Therapeutic approaches to opioid use disorder: what is the current standard of care?. Int J Gen Med 2021; 14: 2305-2311
• 47 Chou R, Weimer MB, Dana T. Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on problems of drug dependence clinical practice guideline. J Pain 2014; 15 (04) 338-365
• 48 Stallvik M, Nordstrand B, Kristensen Ø, Bathen J, Skogvoll E, Spigset O. Corrected QT interval during treatment with methadone and buprenorphine–relation to doses and serum concentrations. Drug Alcohol Depend 2013; 129 (1-2): 88-93
• 49 Committee Opinion No. Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol 2017; 130 (02) e81-e94
• 50 Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel Jr GD. Opioid detoxification in pregnancy. Obstet Gynecol 1998; 92 (05) 854-858
• 51 Stewart RD, Nelson DB, Adhikari EH. et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol 2013; 209 (03) 267.e1-267.e5
• 52 Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ. Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women. Pharmacotherapy 2017; 37 (07) 824-839
• 53 U.S. Food and Drug Administration. Highlights of prescribing information: dolophine (methadone hydrochloride). Silver Spring, MD: U.S. Food and Drug Administration; 2014. Accessed November 22, 2022 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/006134s038lbl.pdf
• 54 Sachs HC. Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics 2013; 132 (03) e796-e809
• 55 Capata M, Hartwell K. Opioid antagonist treatment of opioid-related disorders. In: Brady K, Levin F, Galanter M, Kleber H. eds. The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment. 6th ed.. American Psychiatric Association Publishing; 2021
• 56 Brunström M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med 2018; 178 (01) 28-36
• 57 Lev R, Petro S, Lee A. et al. Methadone related deaths compared to all prescription related deaths. Forensic Sci Int 2015; 257: 347-352
• 58 Dasgupta N, Freifeld C, Brownstein JS. et al. Crowdsourcing black market prices for prescription opioids. J Med Internet Res 2013; 15 (08) e178
• 59 Madden ME, Shapiro SL. The methadone epidemic: methadone-related deaths on the rise in Vermont. Am J Forensic Med Pathol 2011; 32 (02) 131-135
• 60 Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther 2020; 9 (01) 41-54
• 61 Weinstein ZM, Gryczynski G, Cheng DM. et al. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program. Drug Alcohol Depend 2018; 189: 166-171
• 62 Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003; 70 (2, suppl): S59-S77
• 63 Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003; 70 (2, suppl): S13-S27
• 64 Preston KL, Bigelow GE, Liebson IA. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend 1990; 25 (01) 27-34
• 65 Brixadi, Sublocade competitor, resubmits application to FDA. Alcohol Drug Abuse Wkly 2021; 33 (25) 8
• 66 Lewis JW. Buprenorphine. Drug Alcohol Depend 1985; 14 (3-4): 363-372
• 67 Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35 (04) 501-516
• 68 Public Law 115-271 - Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act. Accessed May 22, 2024 at: https://www.govinfo.gov/app/details/PLAW-115publ2712018
• 69 Substance Abuse and Mental Health Services Administration. Statutes, Regulations, and Guidelines. Accessed August 29, 2020 at: https://www.samhsa.gov/medications-substance-use-disorders/statutes-regulations-guidelines
• 70 U.S. Department of Health & Human Services. Removal of DATA Waiver (X-Waiver) Requirement. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2023. Accessed February 7, 2023 at: https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement
• 71 Oesterle TS, Kolla B, Risma CJ. et al. Substance use disorders and telehealth in the COVID-19 pandemic era: a new outlook. Mayo Clin Proc 2020; 95 (12) 2709-2718
• 72 Antoine D, Huhn AS, Strain EC. et al. Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine/naloxone. Am J Addict 2021; 30 (01) 83-87
• 73 Greenwald MK, Herring AA, Perrone J, Nelson LS, Azar P. A neuropharmacological model to explain buprenorphine induction challenges. Ann Emerg Med 2022; 80 (06) 509-524
• 74 Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004
• 75 Lizasoain I, Leza JC, Lorenzo P. Buprenorphine: bell-shaped dose-response curve for its antagonist effects. Gen Pharmacol 1991; 22 (02) 297-300
• 76 Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med 2020; 14 (02) 95-98
• 77 TIP 63: Medications for Opioid Use Disorder - Full Document | SAMHSA publications and digital products. Accessed May 22, 2024 at: https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP21-02-01-0022021
• 78 Samples H, Williams AR, Crystal S, Olfson M. Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid. Health Aff (Millwood) 2020; 39 (05) 747-755
• 79 Dalsbo TK, Steiro A, Stromme H, Reinar LM. Effectiveness of Tapering from Methadone or Buprenorphine Maintenance Treatment Compared to Traditional Maintenance Treatment for People with Opiate Addiction: Systematic Review. Oslo: Norway; 2017
• 80 Li X, Shorter D, Kosten TR. Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies. Expert Opin Pharmacother 2014; 15 (15) 2263-2275
• 81 Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med 2015; 9 (05) 358-367
• 82 Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev 2016; (05) CD011117
• 83 Blum K, Han D, Modestino EJ. et al. A systematic, intensive statistical investigation of data from the comprehensive analysis of reported drugs (CARD) for compliance and illicit opioid abstinence in substance addiction treatment with buprenorphine/naloxone. Subst Use Misuse 2018; 53 (02) 220-229
• 84 Ling W, Charuvastra C, Collins JF. et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93 (04) 475-486
• 85 Hser YI, Saxon AJ, Huang D. et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014; 109 (01) 79-87
• 86 Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2014 (02) CD002207
• 87 Isbister GK, Brown AL, Gill A, Scott AJ, Calver L, Dunlop AJ. QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings. Br J Clin Pharmacol 2017; 83 (10) 2274-2282
• 88 Petry NM, Bickel WK, Piasecki D, Marsch LA, Badger GJ. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000; 9 (03) 265-269
• 89 Saxon AJ, Ling W, Hillhouse M. et al. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013; 128 (1-2): 71-76
• 90 Johnson H, Paulozzi L, Porucznik C, Mack K, Herter B. Hal Johnson Consulting and Division of Disease Control and Health Promotion, Florida Department of Health. Decline in drug overdose deaths after state policy changes - Florida, 2010-2012. MMWR Morb Mortal Wkly Rep 2014; 63 (26) 569-574
• 91 Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ. Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes. Drug Alcohol Depend 2013; 132 (03) 580-586
• 92 Reynaud M, Tracqui A, Petit G, Potard D, Courty P. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry 1998; 155 (03) 448-449
• 93 Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict 2013; 22 (03) 252-254
• 94 Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol 2015; 125 (02) 363-368
• 95 Reckitt Benckiser Healthcare (UK) Ltd. Highlights of prescribing information: Subutex (buprenorphine). Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2002. . Accessed November 22, 2022 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020732s006s007lbl.pdf
• 96 Langabeer JR, Stotts AL, Cortez A, Tortolero G, Champagne-Langabeer T. Geographic proximity to buprenorphine treatment providers in the U.S. Drug Alcohol Depend 2020; 213: 108131
• 97 Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev 2011; 4 (01) 28-41
• 98 Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. Drug Alcohol Depend 2018; 193: 117-123
• 99 Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 1984; 45 (9 Pt 2): 15-19
• 100 Verebey K. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics. NIDA Res Monogr 1981; 28: 147-158
• 101 Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011; 2011 (04) CD001333
• 102 Lee JD, Nunes Jr EV, Novo P. et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018; 391 (10118): 309-318
• 103 Kleber HD. Naltrexone. J Subst Abuse Treat 1985; 2 (02) 117-122
• 104 Bigelow GE, Preston KL, Schmittner J, Dong Q, Gastfriend DR. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend 2012; 123 (1-3): 57-65
• 105 Blumberg H, Dayton HB. Naloxone, naltrexone, and related noroxymorphones. Adv Biochem Psychopharmacol 1973; 8 (00) 33-43
• 106 Bisaga A, Mannelli P, Sullivan MA. et al. Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies. Am J Addict 2018; 27 (03) 177-187
• 107 Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse 2012; 38 (03) 187-199
• 108 Sullivan M, Bisaga A, Pavlicova M. et al. Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. Am J Psychiatry 2017; 174 (05) 459-467
• 109 Bisaga A, Mannelli P, Yu M. et al. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: a phase 3 randomized trial. Drug Alcohol Depend 2018; 187: 171-178
• 110 Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 2006; 101 (04) 491-503
• 111 Gold MS, Dackis CA, Washton AM. The sequential use of clonidine and naltrexone in the treatment of opiate addicts. Adv Alcohol Subst Abuse 1984; 3 (03) 19-39
• 112 Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) 2002; 159 (04) 351-360
• 113 Sullivan MA, Bisaga A, Pavlicova M. et al. A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry 2019; 176 (02) 129-137
• 114 Brewer C, Streel E. Long-acting naltrexone has long-acting benefits and 100% induction rates are not difficult to achieve. Addiction 2019; 114 (01) 188-189
• 115 Garbutt JC, Kranzler HR, O'Malley SS. et al; Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293 (13) 1617-1625
• 116 Darpo B, Zhou M, Bai SA, Ferber G, Xiang Q, Finn A. Differentiating the effect of an opioid agonist on cardiac repolarization from µ-receptor-mediated, indirect effects on the QT interval: a randomized, 3-way crossover study in healthy subjects. Clin Ther 2016; 38 (02) 315-326
• 117 Tetrault JM, Tate JP, McGinnis KA. et al; Veterans Aging Cohort Study Team. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res 2012; 36 (02) 318-324
• 118 Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs 2012; 73 (06) 991-997
• 119 Jones CW, Terplan M. Pregnancy and naltrexone pharmacotherapy. Obstet Gynecol 2018; 132 (04) 923-925
• 120 Chan CF, Page-Sharp M, Kristensen JH, O'Neil G, Ilett KF. Transfer of naltrexone and its metabolite 6,beta-naltrexol into human milk. J Hum Lact 2004; 20 (03) 322-326
• 121 Duramed Pharmaceuticals Inc. REVIA®. Cincinnati, OH: Duramed Pharmaceuticals, Inc.; 2013. . Accessed November 22, 2022 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf
• 122 Harrison TK, Kornfeld H, Aggarwal AK, Lembke A. Perioperative considerations for the patient with opioid use disorder on buprenorphine, methadone, or naltrexone maintenance therapy. Anesthesiol Clin 2018; 36 (03) 345-359
• 123 Anderson TA, Quaye ANA, Ward EN, Wilens TE, Hilliard PE, Brummett CM. To stop or not, that is the question: acute pain management for the patient on chronic buprenorphine. Anesthesiology 2017; 126 (06) 1180-1186